Intranasal Drug Delivery Devices Market Size, Growth, Demands Outlook and Forecasts to 2030

According to the research report, the global intranasal drug delivery devices market size is expected to touch USD 2.98 Billion by 2030, from USD 1.17 Billion in 2020, growing with a significant CAGR of 12.8% from 2021 to 2030.

Intranasal Drug Delivery Devices Market Size 2017 to 2030

The intranasal drug delivery devices market report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global intranasal drug delivery devices market in conjunction with the geographical landscape of this vertical have also been included in this report.

The report offers intricate dynamics about different aspects of the global intranasal drug delivery devices market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global intranasal drug delivery devices market during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

Sample Link @ https://www.precedenceresearch.com/sample/1253

Market Scope

Report Highlights	Details
Market Size	US$ 2.98 Billion by 2030
Growth Rate	CAGR of 12.8% from 2021 to 2030
Base Year	2020
Historic Data	2017 to 2020
Forecast Period	2021 to 2030
Segments Covered	CAGR of 12.8% during the forecast period 2021 to 2030.

This study covers a detailed segmentation of the global intranasal drug delivery devices market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global intranasal drug delivery devices market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Key Players

Johnson & Johnson, Inc.
Aptar Pharma Group
GlaxoSmithKline Plc
Aegis Therapeutics LLC
H&T Presspart Manufacturing Ltd.
AstraZeneca Plc
Becton, Dickinson and Company
Novartis AG
Teleflex Incorporated
Vectura Group Plc.

Market Segmentation

By System

Metered Dose
Multi-Dose Systems
Unit-Dose Systems

By Container

Non-Pressurized Containers
Pressurized Containers

By Application

Chronic Obstructive Pulmonary Disease (COPD)
Rhinitis
Cystic Fibrosis
Nasal Congestion
Asthma
Others

By End User

Ambulatory Surgical Centers
Clinics
Hospitals
Others

By Geography

North America

U.S.
Canada

Europe

Germany
France
United Kingdom
Rest of Europe

Asia Pacific

China
Japan
India
Southeast Asia
Rest of Asia Pacific

Latin America

Brazil
Rest of Latin America

Middle East & Africa (MEA)

GCC
North Africa
South Africa
Rest of Middle East & Africa

Research Methodology

The research methodology adopted by analysts for compiling the global intranasal drug delivery devices market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global intranasal drug delivery devices market.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Intranasal Drug Delivery Devices Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Intranasal Drug Delivery Devices Market

5.1. Covid-19: Intranasal Drug Delivery Devices Industry Impact
5.2. Intranasal Drug Delivery Devices Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Intranasal Drug Delivery Devices Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Intranasal Drug Delivery Devices Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Intranasal Drug Delivery Devices Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. High prevalence of cardiovascular diseases
6.1.1.2. Patent expiration of popular drugs, increased cases of cancer and diabetes
6.1.2. Market Restraints
6.1.2.1. Complications Associated with the Overuse
6.1.3. Market Opportunities
6.1.3.1. Growing adoption of self-administration practices
6.1.3.2. Technological advancements

Chapter 7. Global Intranasal Drug Delivery Devices Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Intranasal Drug Delivery Devices Market Revenue by Market Players (2016 -2019)
7.1.1.2. Intranasal Drug Delivery Devices Market Revenue Market Share by Market Players (2016 -2019)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, System Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Intranasal Drug Delivery Devices Market, By System

8.1. Intranasal Drug Delivery Devices Market, by System, 2016-2027
8.1.1. Metered Dose
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Multi-Dose Systems
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. Unit-Dose Systems
8.1.3.1. Market Revenue and Forecast (2016-2027)

Chapter 9. Global Intranasal Drug Delivery Devices Market, By Container

9.1. Intranasal Drug Delivery Devices Market, by Container, 2016-2027
9.1.1. Non-Pressurized Containers
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Pressurized Containers
9.1.2.1. Market Revenue and Forecast (2016-2027)

Chapter 10. Global Intranasal Drug Delivery Devices Market, By Application

10.1. Intranasal Drug Delivery Devices Market, by Application, 2016-2027
10.1.1. Chronic Obstructive Pulmonary Disease (COPD)
10.1.1.1. Market Revenue and Forecast (2016-2027)
10.1.2. Rhinitis
10.1.2.1. Market Revenue and Forecast (2016-2027)
10.1.3. Cystic Fibrosis
10.1.3.1. Market Revenue and Forecast (2016-2027)
10.1.4. Nasal Congestion
10.1.4.1. Market Revenue and Forecast (2016-2027)
10.1.5. Asthma
10.1.5.1. Market Revenue and Forecast (2016-2027)
10.1.6. Others
10.1.6.1. Market Revenue and Forecast (2016-2027)

Chapter 11. Global Intranasal Drug Delivery Devices Market, By End User

11.1. Intranasal Drug Delivery Devices Market, by End User, 2016-2027
11.1.1. Ambulatory Surgical Centers
11.1.1.1. Market Revenue and Forecast (2016-2027)
11.1.2. Clinics
11.1.2.1. Market Revenue and Forecast (2016-2027)
11.1.3. Hospitals
11.1.3.1. Market Revenue and Forecast (2016-2027)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2016-2027)

Chapter 12. Global Intranasal Drug Delivery DevicesMarket, Regional Estimates and Trend Forecast

12.1. North America
12.1.1. Market Revenue Forecast by System(2016-2027)
12.1.2. Market Revenue Forecast by Container(2016-2027)
12.1.3. Market Revenue Forecast by Application(2016-2027)
12.1.4. Market Revenue Forecast by End User (2016-2027)
12.1.5. U.S
12.1.5.1. Market Revenue Forecast (2016-2027)
12.1.6. Canada
12.1.6.1. Market Revenue Forecast (2016-2027)
12.2. Europe
12.2.1. Market Revenue Forecast by System (2016-2027)
12.2.2. Market Revenue Forecast by Container (2016-2027)
12.2.3. Market Revenue Forecast by Application (2016-2027)
12.2.4. Market Revenue Forecast by End User (2016-2027)
12.2.5. UK
12.2.5.1. Market Revenue Forecast (2016-2027)
12.2.6. Germany
12.2.6.1. Market Revenue Forecast (2016-2027)
12.2.7. France
12.2.7.1. Market Revenue Forecast (2016-2027)
12.2.8. Rest of EU
12.2.8.1. Market Revenue Forecast (2016-2027)
12.3. Asia Pacific (APAC)
12.3.1. Market Revenue Forecast by System (2016-2027)
12.3.2. Market Revenue Forecast by Container (2016-2027)
12.3.3. Market Revenue Forecast by Application (2016-2027)
12.3.4. Market Revenue Forecast by End User (2016-2027)
12.3.5. China
12.3.5.1. Market Revenue Forecast (2016-2027)
12.3.6. India
12.3.6.1. Market Revenue Forecast (2016-2027)
12.3.7. Japan
12.3.7.1. Market Revenue Forecast (2016-2027)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue Forecast (2016-2027)
12.4. LATAM
12.4.1. Market Revenue Forecast by System (2016-2027)
12.4.2. Market Revenue Forecast by Container (2016-2027)
12.4.3. Market Revenue Forecast by Application (2016-2027)
12.4.4. Market Revenue Forecast by End User (2016-2027)
12.4.5. Brazil
12.4.5.1. Market Revenue Forecast (2016-2027)
12.4.6. Rest of LATAM
12.4.6.1. Market Revenue Forecast (2016-2027)
12.5. Middle East and Africa (MEA)
12.5.1. Market Revenue Forecast by System (2016-2027)
12.5.2. Market Revenue Forecast by Container (2016-2027)
12.5.3. Market Revenue Forecast by Application (2016-2027)
12.5.4. Market Revenue Forecast by End User (2016-2027)
12.5.5. GCC
12.5.5.1. Market Revenue Forecast (2016-2027)
12.5.6. North Africa
12.5.6.1. Market Revenue Forecast (2016-2027)
12.5.7. South Africa
12.5.7.1. Market Revenue Forecast (2016-2027)
12.5.8. Rest of MEA
12.5.8.1. Market Revenue Forecast (2016-2027)

Chapter 13. Company Profiles

13.1. Johnson & Johnson, Inc.
13.1.1. Company Overview, Business Information, Regional Presence
13.1.2. Product Portfolio Analysis
13.1.2.1. Product Details, Specification, Application
13.1.3. Revenue, Price, and Gross Margin (2015-2020)
13.1.4. Recent Developments and Strategies
13.2. Aptar Pharma Group
13.2.1. Company Overview, Business Information, Regional Presence
13.2.2. Product Portfolio Analysis
13.2.2.1. Product Details, Specification, Application
13.2.3. Revenue, Price, and Gross Margin (2015-2020)
13.2.4. Recent Developments and Strategies
13.3. GlaxoSmithKline Plc
13.3.1. Company Overview, Business Information, Regional Presence
13.3.2. Product Portfolio Analysis
13.3.2.1. Product Details, Specification, Application
13.3.3. Revenue, Price, and Gross Margin (2015-2020)
13.3.4. Recent Developments and Strategies
13.4. Aegis Therapeutics LLC
13.4.1. Company Overview, Business Information, Regional Presence
13.4.2. Product Portfolio Analysis
13.4.2.1. Product Details, Specification, Application
13.4.3. Revenue, Price, and Gross Margin (2015-2020)
13.4.4. Recent Developments and Strategies
13.5. H&T Presspart Manufacturing Ltd.
13.5.1. Company Overview, Business Information, Regional Presence
13.5.2. Product Portfolio Analysis
13.5.2.1. Product Details, Specification, Application
13.5.3. Revenue, Price, and Gross Margin (2015-2020)
13.5.4. Recent Developments and Strategies
13.6. AstraZeneca Plc
13.6.1. Company Overview, Business Information, Regional Presence
13.6.2. Product Portfolio Analysis
13.6.2.1. Product Details, Specification, Application
13.6.3. Revenue, Price, and Gross Margin (2015-2020)
13.6.4. Recent Developments and Strategies
13.7. Becton, Dickinson and Company
13.7.1. Company Overview, Business Information, Regional Presence
13.7.2. Product Portfolio Analysis
13.7.2.1. Product Details, Specification, Application
13.7.3. Revenue, Price, and Gross Margin (2015-2020)
13.7.4. Recent Developments and Strategies
13.8. Novartis AG
13.8.1. Company Overview, Business Information, Regional Presence
13.8.2. Product Portfolio Analysis
13.8.2.1. Product Details, Specification, Application
13.8.3. Revenue, Price, and Gross Margin (2015-2020)
13.8.4. Recent Developments and Strategies
13.9. Teleflex Incorporated
13.9.1. Company Overview, Business Information, Regional Presence
13.9.2. Product Portfolio Analysis
13.9.2.1. Product Details, Specification, Application
13.9.3. Revenue, Price, and Gross Margin (2015-2020)
13.9.4. Recent Developments and Strategies
13.10. Vectura Group Plc.
13.10.1. Company Overview, Business Information, Regional Presence
13.10.2. Product Portfolio Analysis
13.10.2.1. Product Details, Specification, Application
13.10.3. Revenue, Price, and Gross Margin (2015-2020)
13.10.4. Recent Developments and Strategies